We report on a multifunctional nucleic acid, termed AptamiR, composed of an aptamer domain and an antimiR domain. This composition mediates cell specific delivery of antimiR molecules for silencing of endogenous micro RNA. The introduced multifunctional molecule preserves cell targeting, anti-proliferative and antimiR function in one 37-nucleotide nucleic acid molecule. It inhibits cancer cell growth and induces gene expression that is pathologically damped by an oncomir. These findings will have a strong impact on future developments regarding aptamer- and antimiR-related applications for tumor targeting and treatment.
Get full access to this article
View all access options for this article.
References
1.
BATESP.J., LABERD.A., MILLERD.M., THOMASS.D., and TRENTJ.O. (2009). Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp. Mol. Pathol., 86, 151–164.
2.
CHOW.C. (2007). OncomiRs: the discovery and progress of microRNAs in cancers. Mol. Cancer, 6, 60.
3.
CHUT.C., MARKSJ.W.3rd, LAVERYL.A., FAULKNERS., ROSENBLUMM.G., ELLINGTONA.D., and LEVYM. (2006). Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res., 66, 5989–5992.
FAROKHZADO.C., CHENGJ., TEPLYB.A., SHERIFII., JONS., KANTOFFP.W., RICHIEJ.P., and LANGERR. (2006). Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. U. S. A., 103, 6315–6320.
6.
KANASTYR.L., WHITEHEADK.A., VEGASA.J., and ANDERSOND.G. (2012). Action and Reaction: The Biological Response to siRNA and Its Delivery Vehicles. Mol. Ther., 20, 513–524.
7.
KRICHEVSKYA.M., and GABRIELYG. (2009). miR-21: a small multi-faceted RNA. J. Cell Mol. Med., 13, 39–53.
8.
LANFORDR.E., HILDEBRANDT-ERIKSENE.S., PETRIA., PERSSONR., LINDOWM., MUNKM.E., KAUPPINENS., and ORUMH. (2010). Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science, 327, 198–201.
LOUY., CUIZ., WANGF., YANGX., and QIANJ. (2011). miR-21 down-regulation promotes apoptosis and inhibits invasion and migration abilities of OVCAR3 cells. Clin. Invest. Med., 34, E281.
11.
MALIKR., and ROYI. (2011). Making sense of therapeutics using antisense technology. Expert Opin. Drug Discov., 6, 507–526.
12.
MAYERG. (2009). The chemical biology of aptamers. Angew Chem. Int. Ed. Engl., 48, 2672–2689.
13.
MAYERG., AHMEDM.S., DOLFA., ENDLE., KNOLLEP.A., and FAMULOKM. (2010). Fluorescence-activated cell sorting for aptamer SELEX with cell mixtures. Nat. Protoc., 5, 1993–2004.
14.
MCNAMARAJ.O.2nd, ANDRECHEKE.R., WANGY., VILESK.D., REMPELR.E., GILBOAE., SULLENGERB.A., and GIANGRANDEP.H. (2006). Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol., 24, 1005–1015.
15.
MONGELARDF., and BOUVETP. (2010). AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia. Curr. Opin. Mol. Ther., 12, 107–114.
16.
OBADS., DOS SANTOSC.O., PETRIA., HEIDENBLADM., BROOMO., RUSEC., FUC., LINDOWM., STENVANGJ., STRAARUPE.M., et al. (2011). Silencing of microRNA families by seed-targeting tiny LNAs. Nat. Genet., 43, 371–378.
17.
REYES-REYESE.M., TENGY., and BATESP.J. (2010). A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer Res., 70, 8617–8629.
18.
SEFAHK., SHANGGUAND., XIONGX., O'DONOGHUEM.B., and TANW. (2010). Development of DNA aptamers using Cell-SELEX. Nat. Protoc., 5, 1169–1185.
19.
SOUNDARARAJANS., CHENW., SPICERE.K., COURTENAY-LUCKN., and FERNANDESD.J. (2008). The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res., 68, 2358–2365.
20.
STEINC.A., HANSENJ.B., LAIJ., WUS., VOSKRESENSKIYA., HOGA., WORMJ., HEDTJARNM., SOULEIMANIANN., MILLERP., et al. (2010). Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res., 38, e3.
21.
TENGY., GIRVANA.C., CASSONL.K., PIERCEW.M.JR., QIANM., THOMASS.D., and BATESP.J. (2007). AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin. Cancer Res., 67, 10491–10500.
22.
TONGA.W., and NEMUNAITISJ. (2008). Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy?. Cancer Gene Ther., 15, 341–355.
23.
YANL.X., WUQ.N., ZHANGY., LIY.Y., LIAOD.Z., HOUJ.H., FUJ., ZENGM.S., YUNJ.P., WUQ.L., et al. (2011). Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res., 13, R2.
24.
ZHOUJ., LIH., ZHANGJ., PIOTRS., and ROSSIJ. (2011). Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery. J. Vis. Exp., 52, 2954.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
